? Top 10 Healthcare Small-Cap Stocks 2025

? Lead Program: Rezpegaldesleukin (REZPEG)

First-in-class regulatory T-cell stimulator: Phase 2b REZOLVE-AD (atopic dermatitis). Emerging data show unique ability to treat both AD AND co-morbid asthma (~25% of AD patients). Differentiated vs. Dupilumab (Regeneron).

• Dec 2025 (CRITICAL): REZPEG Phase 2 alopecia areata readout. Key to Phase 3 pathway.
• Q1 2026: Potential Phase 3 AD initiation if REZOLVE-AD data supportive.

? Obexelimab: Bifunctional B-Cell Inhibitor

Lead Catalyst: Phase 3 INDIGO IgG4-Related Disease (IgG4-RD). ? Topline readout YEAR-END 2025 (WEEKS AWAY). Phase 2 showed 100% of completers met primary endpoint. Orphan disease with high unmet need.

• Q4 2025: Phase 2 MoonStone (RMS) results
• BMS Partnership: $50M upfront + $20M equity investment

? Healthcare Services Platform

Prestige Global: Healthcare provision resource platform serving personal and institutional clients. Operates healthcare administration, facility management, consulting.

• Back-office management for SNFs (skilled nursing facilities) and ALFs (assisted living facilities)
• Financial, accounting, payroll, compliance management
• Regional director oversight + operational guidance

? FDA-Cleared Smart Baby Monitor

Owlet Dream Sock: Wearable monitoring infant heart rate, oxygen, sleep. Medically-validated; 1M+ parents. Q3 blowout: +44.6% revenue, positive EBITDA.

• Early 2026: Commercial launch India (major TAM expansion)
• Ongoing: Owlet OnCall telehealth + Owlet360 subscription growth
• FY2025 Raised Guidance: $103–106M revenue (from $88–92M)

? Full-Service Genomic Testing Platform

Divisions: Fulgent Oncology (hereditary cancer testing), Fulgent BioPharma (therapeutics), Picture Genetics (prenatal), HelioLiver (liver diagnostics).

• Nov 2025: EU CE certification for FulgentExome—first lab with comprehensive germline offering
• Nov 2025: KNOVA Prenatal launch (56+ monogenic conditions, differentiated vs. NIPT)
• Ongoing: Volume growth in oncology testing, VA partnerships expanding

? BDTX-1535: Precision Oncology TKI

Lead Program: Oral tyrosine kinase inhibitor targeting EGFR mutations in NSCLC + glioblastoma. Phase 2 ongoing.

• ? Q1 2026 (CRITICAL): Phase 2 NSCLC readouts (EGFR-mutant, recurrent cohorts). Potential registrational pathway emerges.
• 2026: BDTX-4933 partnership announcement (CNS-penetrant BRAF inhibitor)

? Profitable: Government MCM Contracts + Commercial Products

MCM Portfolio: BioThrax (anthrax vaccine), ACAM2000 (smallpox), NARCAN (naloxone nasal spray). Government recurring contracts + commercial growth.

• Q3 Blowout: Revenue beat expectations, 11 MCM contract modifications secured in 2025
• NARCAN Growth: OTC availability expanding
• FY2025 Raised Guidance: Higher revenue + profitability

? Regenerative Tissue Products

Portfolio: Apligraf (VLU/DFU), Dermagraft (DFU), PuraPly (barriers), Affinity (allografts).

• May 2025: Announced $100M+ Smithfield facility investment (122,000 sq-ft biomanufacturing)
• Timeline: Multi-year ramp (2025-2027+). Dermagraft production resumption + Apligraf scaling
• Expected 200+ jobs in New England hub

? Specialty Pharma Platform

Dual Revenue: Cortrophin Gel (branded rare disease, Q3 2024: $26.1M strong growth) + Generics portfolio (68% of revenue) + CDMO services.

• Cortrophin Expansion: Continued penetration in indications
• Generic Portfolio: 5–10 new launches annually (ANDA filings)
• Acquisitions: Proven playbook (Novitium Pharma 2021)

? Anaphylm: Needle-Free Epinephrine Film

Lead Product: Anaphylm™ sublingual epinephrine film for Type 1 allergic reactions/anaphylaxis. Differentiated: no needles, easy administration.

• Q1 2025: NDA submitted to FDA
• Sept 2025: FDA decision: NO advisory committee meeting required (smoother path)
• ? Jan 2026 (CRITICAL): FDA approval decision date
• Q1 2026: Potential US launch if approved

Additional Pipeline: Libervant® (FDA-approved oral seizure rescue, pediatric 2-5), AQST-108 (topical gel, alopecia areata Phase 2a Q2 2025)